At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18 enrolled
Drug / intervention
Omnipaque 240 Contrast Solution +2 moredrug
Likely dose
Omnipaque 240 mg I/mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison
In Brief
A clinical study evaluating Sinus CT Scan, Omnipaque 240 Contrast Solution, and 1 other intervention for Chronic Sinusitis. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Sinusitis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartMar 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedFeb 29, 2008
Enrollment StartMar 12, 2008
Primary CompletionJan 9, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.3 years ago
Interventions
Sinus CT Scanradiation
Subjects will undergo a Xoran miniCAT scan of their sinuses
Omnipaque 240 Contrast Solutiondrug
Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
Omnipaque 240 mg I/mLdrug
Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.